FDA Approves BioCryst's Emergency Swine Flu Treatment

BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) received FDA approval for its experimental drug to be used as emergency treatment for swine flu sending the stock price soaring 98 cents to $10.65.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.